MENU
BBP
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

BBP stock forecast, quote, news & analysis

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
BBP
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BBP with price predictions
Oct 07, 2026

BBP sees MACD Histogram just turned negative

BBP saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 52 instances where the indicator turned negative. In 42 of the 52 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBP as a result. In 70 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

BBP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBP advanced for three days, in 282 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

BBP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 226 of 257 cases where BBP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.

Market Cap

The average market capitalization across the Virtus Biotech ETF (BBP) ETF is 19.01B. The market cap for tickers in the group ranges from 594.62M to 226.05B. AMGN holds the highest valuation in this group at 226.05B. The lowest valued company is PHAT at 594.62M.

High and low price notable news

The average weekly price growth across all stocks in the Virtus Biotech ETF (BBP) ETF was 10%. For the same ETF, the average monthly price growth was 53%, and the average quarterly price growth was 282%. XERS experienced the highest price growth at 6%, while NUVB experienced the biggest fall at -13%.

Volume

The average weekly volume growth across all stocks in the Virtus Biotech ETF (BBP) ETF was -37%. For the same stocks of the ETF, the average monthly volume growth was 31% and the average quarterly volume growth was -46%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 66
Price Growth Rating: 55
SMR Rating: 73
Profit Risk Rating: 69
Seasonality Score: 18 (-100 ... +100)
BBP sees MACD Histogram just turned negative